

Product Datasheet

DCC-3116

Catalog No. **BP-02028** · CAS **2543673-19-2** · Form **free base** · Physical state **other** · Color **White to light yellow** · Version **1.0**
 · Revision **2026-09-02**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target ULK; Ras; Autophagy	Research area Cancer
--------------------------------------	--------------------------------

Molecular formula **C₂₆H₃₆F₃N₇O₂**

Molecular weight **535.6049**

STRUCTURE



DESCRIPTION

DCC-3116 is an orally active ULK1/2 inhibitor. DCC-3116 can promote autophagy in lung cancer cells by inhibiting KRASG12C signaling, thereby inhibiting the proliferation of lung cancer cells and exerting anti-cancer effects.

BIOLOGICAL ACTIVITY

In Vivo

DCC-3116 (3 or 30 mg/kg/day for 56 days, p.o. and p.i.) alone or in combination with Sotorasib (HY-114277) can inhibit tumor growth in mouse models of NSCLC lung cancer.

In Vitro

DCC-3116 (100 nM, 72 h) alone inhibits the proliferation of NCI-H2122 and Calu-1 cells, decreases the expression of pS318-ATG13, and has a synergistic effect when combined with Sotorasib (HY-114277).

SOLUBILITY

Soluble in DMSO : 100 mg/mL

REFERENCES

[1]. Ghazi PC, et al. Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer. bioRxiv [Preprint]. 2024 Feb 8:2024.02.06.579200.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.